SAR1B

SAR1B is a small GTPase that drives COPII vesicle coat assembly at the endoplasmic reticulum membrane, enabling ER-to-Golgi transport of cargo including chylomicrons, lipoproteins, and the cardiac sodium channel Nav1.5 (PMID:15017362, PMID:28982670, PMID:30251687). In intestinal enterocytes, SAR1B resides in a cytosolic complex with FABP1, Sec13, and SVIP; phosphorylation by PKCζ disassembles this complex, freeing FABP1 to bind ER and initiate pre-chylomicron transport vesicle budding (PMID:22303004). Independent of its vesicle-trafficking role, SAR1B functions as a direct intracellular leucine sensor that binds and inhibits GATOR2 under leucine deficiency, thereby suppressing mTORC1 signaling, and dissociates from GATOR2 upon leucine-induced conformational change (PMID:34290409). Loss-of-function mutations in SAR1B cause chylomicron retention disease (Anderson disease), confirmed by mouse genetic models showing late-gestation lethality in homozygous knockouts and impaired chylomicron secretion in heterozygotes, with SAR1A and SAR1B being functionally interchangeable in vivo (PMID:33964306, PMID:38687799).

1. 2004 High

   Establishing SAR1B as the causative gene for chylomicron retention disease resolved how enterocytes export chylomicrons and linked COPII vesicle machinery to intestinal lipid transport.

   Evidence Genetic analysis of patient mutations and structural data on Sar1–Sec23/24 complex

   PMID:15017362

   Open questions at the time

   • How SAR1B selectively handles chylomicron-sized cargo versus standard COPII vesicles was unknown
   • Degree of functional overlap with SAR1A was not addressed
2. 2011 Medium

   Demonstrating that SAR1B overexpression enhances COPII assembly, chylomicron production, and SREBP-1c nuclear transfer revealed that SAR1B levels are rate-limiting for intestinal lipoprotein biogenesis and lipogenic transcription.

   Evidence Overexpression in Caco-2/15 cells with co-immunoprecipitation, enzymatic activity assays, and Western blot

   PMID:21836065

   Open questions at the time

   • Overexpression system may not reflect physiological regulation
   • Whether SREBP-1c nuclear transfer is a direct consequence of COPII assembly or a secondary effect was unclear
3. 2012 High

   Identifying the 75-kDa SAR1B–FABP1–Sec13–SVIP cytosolic complex and showing that PKCζ phosphorylation of SAR1B disassembles it to enable PCTV budding revealed the regulatory switch controlling pre-chylomicron vesicle formation.

   Evidence Size-exclusion chromatography, LC-MS/MS, MALDI-TOF, in vitro phosphorylation with PKCζ, ER binding assay using native intestinal cytosol

   PMID:22303004

   Open questions at the time

   • The specific phosphorylation site(s) on SAR1B were not mapped
   • Whether this complex exists in non-intestinal cells was not tested
4. 2012 Medium

   Showing that SAR1B lowers membrane bending rigidity provided a biophysical mechanism for how COPII GTPases deform ER membranes to initiate vesicle budding.

   Evidence Optical trap-based membrane deformation assay with purified human SAR1B protein

   PMID:22974979

   Open questions at the time

   • Measurements were on synthetic membranes; relevance to ER membrane composition not confirmed
   • Concentration-dependent rigidity increase at high densities not mechanistically explained
5. 2017 High

   Genetic knockout of SAR1B in enterocytes quantified its contribution to chylomicron secretion (~35% reduction) and demonstrated partial compensation by SAR1A, establishing that double knockout nearly abolishes lipoprotein output.

   Evidence Zinc finger nuclease knockout of SAR1B and SAR1A/B in Caco-2/15 cells with lipid secretion and cholesterol efflux assays

   PMID:28982670

   Open questions at the time

   • In vivo relevance in whole-animal models was not yet shown
   • Mechanism of SAR1A compensation was unclear
6. 2018 Medium

   Demonstrating that SAR1B regulates Nav1.5 trafficking to the cell surface via interaction with MOG1 extended SAR1B's cargo repertoire beyond lipoproteins to ion channels with cardiac relevance.

   Evidence Dominant-negative mutants, siRNA knockdown, co-immunoprecipitation, patch-clamp electrophysiology in HEK/Nav1.5 cells and neonatal cardiomyocytes

   PMID:30251687

   Open questions at the time

   • Direct physical interaction between SAR1B and Nav1.5 was not shown; interaction is via MOG1
   • In vivo cardiac phenotype of SAR1B loss was not examined
7. 2019 Medium

   Showing that SAR1B knockout activates mitochondrial β-oxidation via PPARα/PGC1α and triggers NF-κB/NRF2-mediated inflammatory and oxidative stress responses revealed that SAR1B loss has broad metabolic and stress-signaling consequences beyond secretion defects.

   Evidence CRISPR/Cas9 knockout in Caco-2/15 cells with metabolic and transcriptional readouts

   PMID:31409740

   Open questions at the time

   • Whether metabolic reprogramming is a direct effect or secondary to lipid accumulation was not resolved
   • Single cell line system limits generalizability
8. 2020 Medium

   Demonstrating that SAR1B knockdown impairs cortical neuron radial migration and axon morphogenesis established a cell-autonomous developmental role for SAR1B in the brain, independent of its intestinal function.

   Evidence In utero electroporation of shRNA and dominant-negative SAR1B(D137N) in mouse neocortex with immunohistochemistry and neuron tracing

   PMID:33002559

   Open questions at the time

   • The specific cargo whose trafficking is disrupted in migrating neurons was not identified
   • Single lab, single method approach limits confidence
9. 2021 High

   Generating Sar1b knockout and knock-in mice established direct causality between SAR1B mutations and chylomicron retention disease in a mammalian model, with homozygous lethality and heterozygous lipid abnormalities.

   Evidence CRISPR-Cas9 knockout and point-mutation knock-in mice with plasma lipid assays, lipid gavage, fecal lipid quantification

   PMID:33964306

   Open questions at the time

   • Cause of late-gestation lethality in homozygotes was not fully characterized
   • Tissue-specific contributions to lethality were not dissected
10. 2021 High

    Identifying SAR1B as a direct leucine sensor that inhibits mTORC1 via GATOR2 binding revealed a nutrient-sensing function entirely distinct from its COPII vesicle role, expanding SAR1B biology to growth signaling.

    Evidence Co-immunoprecipitation, biochemical binding and conformational change assays, genetic epistasis in C. elegans, siRNA knockdown with mTORC1 activity readout

    PMID:34290409

    Open questions at the time

    • Structural basis of leucine binding to SAR1B and the conformational switch is unknown
    • Whether the leucine-sensing and COPII functions are spatially or temporally segregated in cells is unresolved
11. 2024 High

    Proving that SAR1A and SAR1B are functionally interchangeable in vivo resolved the longstanding question of why SAR1B mutations cause tissue-specific disease despite ubiquitous expression — the answer lies in expression level differences, not protein function.

    Evidence Knock-in of Sar1a coding sequence at endogenous Sar1b locus, hepatocyte-specific conditional knockout, adenovirus rescue in mice

    PMID:38687799

    Open questions at the time

    • Whether interchangeability holds in all tissues (e.g., neurons, enterocytes) was not directly tested
    • Regulatory differences between SAR1A and SAR1B promoters driving tissue-specific disease susceptibility are not characterized

• Key unresolved questions include the structural basis of leucine binding to SAR1B, whether the leucine-sensing and COPII trafficking functions are mechanistically coupled or independent, the cargo responsible for SAR1B's role in cortical neuron migration, and the cause of embryonic lethality upon complete SAR1B loss.
• No crystal structure of SAR1B bound to leucine exists
• Relationship between mTORC1-sensing and COPII vesicle functions is completely unexplored
• Neuronal cargo requiring SAR1B-dependent ER export is unidentified